We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+4.63%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$104M
AUM Growth
-$25.8M
Cap. Flow
-$7.19M
Cap. Flow %
-6.95%
Top 10 Hldgs %
55.77%
Holding
61
New
9
Increased
3
Reduced
31
Closed
18

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$22.6M
2
IBB icon
iShares Biotechnology ETF
IBB
+$4.76M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$3.22M
4
GSK icon
GSK
GSK
+$2.11M
5
IQV icon
IQVIA
IQV
+$1.44M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$3.11M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$2.63M
3
EPZM
Epizyme, Inc
EPZM
+$2.3M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$2.14M
5
PCRX icon
Pacira BioSciences
PCRX
+$1.86M

Sector Composition

Rank Sector Weight
1 Healthcare 63.14%
2 Miscellaneous 35.99%
3 Real Estate 0.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
26
Ionis Pharmaceuticals
IONS
$7.85B
$1.65M 1.59%
70,868
-25,940
-27% -$837K
IQV icon
27
IQVIA
IQV
$44.4B
$1.41M 1.36%
+21,520
New +$1.44M
SNR
28
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$894K 0.86%
83,700
-6,300
-7% -$67.1K
SDS icon
29
ProShares UltraShort S&P500
SDS
$410M
$712K 0.69%
400
-50
-11% -$92.4K
ADMS
30
DELISTED
Adamas Pharmaceuticals
ADMS
$684K 0.66%
45,198
-8,802
-16% -$145K
MCRB icon
31
Seres Therapeutics
MCRB
$46.2M
$591K 0.57%
1,017
-198
-16% -$116K
HOLX
32
DELISTED
Hologic
HOLX
$571K 0.55%
16,500
-22,200
-57% -$769K
PRTK
33
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$524K 0.51%
37,665
-7,335
-16% -$108K
MDCO
34
DELISTED
Medicines Co
MDCO
$467K 0.45%
13,885
-26,615
-66% -$938K
LABU icon
35
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$469M
$413K 0.4%
732
+133
+22% +$83.3K
RARE icon
36
Ultragenyx Pharmaceutical
RARE
$1.29B
$346K 0.33%
7,074
-6,426
-48% -$416K
ISEE
37
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$344K 0.33%
6,746
-5,854
-46% -$291K
UTHR icon
38
United Therapeutics
UTHR
$21.5B
$219K 0.21%
2,064
-1,784
-46% -$199K
NVAX icon
39
Novavax
NVAX
$1.52B
$212K 0.2%
+1,455
New +$167K
CPHD
40
DELISTED
Cepheid Inc
CPHD
$209K 0.2%
+6,782
New +$205K
IOVA icon
41
Iovance Biotherapeutics
IOVA
$4.24B
$196K 0.19%
+24,226
New +$152K
GRFS
42
Grifois
GRFS
$5.01B
$187K 0.18%
+11,188
New +$176K
SIOX
43
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$172K 0.17%
1,674
-1,628
-49% -$163K
AVDL
44
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-69,109
Closed -$763K
BIB icon
45
ProShares Ultra NASDAQ Biotechnology
BIB
$94.3M
– –
-64,462
Closed -$2.63M
EYPT icon
46
EyePoint Inc
EYPT
$316M
– –
-18,000
Closed -$482K
GILD icon
47
Gilead Sciences
GILD
$181B
– –
-3,282
Closed -$301K
IWM icon
48
PUT
iShares Russell 2000 ETF
IWM
$76.9B
– –
-200,000
Closed -$22.1M
KPTI icon
49
Karyopharm Therapeutics
KPTI
$34.9M
– –
-3,300
Closed -$442K
LAB icon
50
Standard BioTools
LAB
$271M
– –
-45,000
Closed -$363K
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q2 2016 Portfolio in Review

As of Q2 2016, Opus Point Partners Management held 61 positions worth $104M, down 20% from $129M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Opus Point Partners Management withdrew a net $7.19M in Q2 2016, closing 18 positions and reducing 31 holdings. Its most notable exit was ProShares Ultra NASDAQ Biotechnology, an estimated $2.63M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 73% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Opus Point Partners Management opened a new position in iShares Russell 2000 ETF worth $23M.

  • Opus Point Partners Management's largest Q2 2016 buy was iShares Russell 2000 ETF: 200,000 shares worth $23M.
  • Opus Point Partners Management added most to AstraZeneca in Q2 2016, an estimated $856K increase.
  • Opus Point Partners Management's biggest Q2 2016 reduction was MEDIVATION, INC., cutting an estimated $3.11M.
  • Opus Point Partners Management fully exited ProShares Ultra NASDAQ Biotechnology in Q2 2016, selling an estimated $2.63M.
  • Opus Point Partners Management's ten largest holdings make up 56% of its $104M portfolio in Q2 2016.
  • Opus Point Partners Management opened 9 new positions and closed 18 in Q2 2016.
  • Opus Point Partners Management's portfolio value fell 20% quarter-over-quarter to $104M.

Based on Opus Point Partners Management's 13F filing for Q2 2016, filed 15 Aug 2016.